Recently, a variety of serum pretreatment markers have been evaluated and taken to assess whether they could provide valuable prognosis information in patients with cancer, including neutrophil-to-lymphocyte ratio (NLR), C-reactive protein to albumin ratio (CAR), and prognostic nutritional index (PNI) [6–8]. This evidence concerns the gene ALB and cancer.